Clinical trial

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

NCT01628393

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-09-18

PhasePHASE2 / PHASE3

Study timeline

Study start (actual)2012-09-18Date precision: day

Registry last updated2021-02-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing Multiple Sclerosisunresolved

Interventions

OzanimodDRUG · verified · RxNorm: ozanimod

PlaceboDRUG

Sponsors & collaborators

Celgenelead sponsor

Mapped research locations

WarsawPoland4 BelgradeSerbia4 KatowicePoland3 AthensGreece2 Cluj-NapocaRomania2 Kazan'Russia2 SeattleWashington, United States1 CharlotteNorth Carolina, United States1 ValenciaSpain1 SacramentoCalifornia, United States1 BrusselsBelgium1 SofiaBulgaria1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01628393 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.